Harrow (HROW) Depreciation & Amortization (CF) (2010 - 2026)
Harrow's (HROW) quarterly Depreciation & Amortization (CF) came in at $455000.0 in Q1 2026, down 2.15% year-on-year from $465000.0 in Q1 2025, and down 1.94% quarter-over-quarter from $464000.0 in Q4 2025.
Harrow (HROW) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Harrow's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $455000.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 2.15% year-over-year to $455000.0 in Q1 2026; TTM through Mar 2026 was $1.9 million, a 1.17% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, up 3.51% from the prior year.
- Depreciation & Amortization (CF) retreated to $455000.0 in Q1 2026 per HROW's latest filing, from $464000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $497000.0 in Q3 2024 and bottomed at $247000.0 in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $435000.0 (2023), against an average of $425117.6.
- Across the five-year window, Depreciation & Amortization (CF) slumped 38.1% in 2022 and surged 63.97% in 2023, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $387000.0 in 2022, then climbed by 12.4% to $435000.0 in 2023, then gained by 7.59% to $468000.0 in 2024, then fell by 0.85% to $464000.0 in 2025, then slipped by 1.94% to $455000.0 in 2026.
- Per Business Quant, the three latest HROW Depreciation & Amortization (CF) figures stand at $455000.0 (Q1 2026), $464000.0 (Q4 2025), and $490000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 455,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 455,000.00 |
| Mar 31, 2026 | 455,000.00 |
| Dec 31, 2025 | 464,000.00 |
| Dec 31, 2025 | 464,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Jun 30, 2025 | 496,000.00 |
| Jun 30, 2025 | 496,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Dec 31, 2024 | 468,000.00 |
| Dec 31, 2024 | 468,000.00 |
| Sep 30, 2024 | 497,000.00 |
| Sep 30, 2024 | 497,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Dec 31, 2023 | 435,000.00 |
| Dec 31, 2023 | 435,000.00 |